Stock Financial Ratios

BTX / BioTime, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price2.74
Volume221,400.00
Market Cap ($M)334.93
Enterprise Value ($M)327.70
Book Value ($M)117.93
Book Value / Share1.06
Price / Book1.68
NCAV ($M)-0.74
NCAV / Share0.00
Price / NCAV-276.54
Income Statement (mra) ($M)
Revenue5.92
EBITDA-58.97
Net Income18.62
Balance Sheet (mrq) ($M)
Cash & Equivalents0.00
Cash / Share0.00
Assets0.00
Liabilities0.00
Quick Ratio
Current Ratio
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.16
Return on Assets (ROA)157.81
Return on Equity (ROE)0.16
Identifiers and Descriptors
CUSIP09066L105
Central Index Key (CIK)876343
Industry Groups
SIC 2836 - Biological Products, Except Diagnostic Substances (Biotech)
Other Related CUSIPS
09066L955
09066L905
Share Statistics
Common Shares Outstanding110,853,754
Common Stock Shares Outstanding102,776,539
Preferred Stock Shares Outstanding0
Weighted Average Number Of Diluted Shares Outstanding99,553,000
Weighted Average Number Of Shares Outstanding Basic97,316,000
Scoring Models
Piotroski F-Score5.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Intangibles Per Share0.00
Accumulated Depreciation And Depletion Per Share0.00
Equity Per Share0.00
Assets Current Per Share0.00
Minority Interest Per Share0.00
Property Plant And Equipment Gross Per Share0.00
Accounts Receivable Per Share0.00
Property Plant And Equipment Per Share0.00
Inventory Raw Materials Per Share0.00
Liabilities Per Share0.00
Long Term Debt Per Share0.00
Treasury Stock Per Share0.00
Cash Per Share0.00
Accounts Payable Per Share0.00
Assets Non Current Per Share0.00
Inventory Per Share0.00
Retained Earnings Per Share0.00
Liabilities And Stock Equity Per Share0.00
Assets Other Non Current Per Share0.00
Inventory Work In Progress Per Share0.00
Goodwill Per Share0.00
Property Plant And Equipment Net Per Share0.00
Additional Paid In Capital Per Share0.00
Liabilities Current Per Share0.00
Debt Per Share0.00
Assets Per Share0.00
Deferred Income Tax Liabilities Per Share0.00
Current Portion Of Long Term Debt Per Share0.00
Cash And Equivalents Per Share0.00
Assets Other Current Per Share0.00
Inventory Finished Goods Per Share0.00
Liabilities Other Non Current Per Share0.00
Preferred Stock Value Outstanding Per Share0.00

Peers - Biological Products, Except Diagnostic Substances (Biotech) (2836)

Related News Stories

BioTime May Very Well Be The Wayne Gretzky Of Clinical Stage Biotech Companies

2018-02-21 seekingalpha
BioTime (BTX) may very well be the Wayne Gretzky of clinical stage biotech companies with countless shots on goal. The mini-conglomerate of stem cell technology has a massive array of market opportunities, in part because of the enormous portfolio of assets acquired from Geron (GERN) in 2013. Not only do I feel BioTime's core business is undervalued by the market, but likewise, its significant investments in publicly traded spin-offs Asterias Biotherapeutics (AST) and OncoCyte (OCX) are also each seemingly underappreciated by the market. (14-0)

BRIEF-BioTime Says Funds Raised Last Year To Fund Operations Well Into 2019​

2018-01-22 reuters
* BIOTIME INC - ‍ FUNDS RAISED TOWARDS END OF LAST YEAR PROVIDE CO SUFFICIENT CAPITAL, AT CURRENTLY PLANNED SPENDING LEVELS, TO FUND OPERATIONS WELL INTO 2019​ Source text for Eikon: Further company coverage: (9-1)

Your Daily Pharma Scoop: Achaogen Is A Compelling Investment, Protalix Gains On Preliminary Results, BioTime Announces Publication Of Results

2018-01-03 seekingalpha
Today we will discuss the latest update from Achaogen (AKAO). AKAO shares surged in early trading on Tuesday after the clinical-stage biotech company moved a step closer to bringing its lead drug candidate, plazomicin, into the market. According to Blake Wise, Achaogen’s CEO, the number of confirmed cases of CRE annually in the U.S. alone total at least 70,000. More important, Wise noted is that the number is projected to double by 2022. (224-6)

Zacks.com highlights: BioTime, Ritter Pharmaceuticals, Organovo Holdings, American Superconductor and Stratasys

2017-12-20 zacks
Chicago, IL – Dec 20, 2017 - Stocks in this week’s article include: BioTime Inc. (BTX - Free Report) , Ritter Pharmaceuticals Inc. (RTTR - Free Report) , Organovo Holdings Inc. (ONVO - Free Report) , American Superconductor Corp. (AMSC - Free Report) and Stratasys Ltd. (SSYS - Free Report) . (116-2)

CUSIP: 09066L105